白细胞介素与肝功能衰竭的关系及其相关机制的研究

摘要/Abstract

摘要： 肝功能衰竭是指由于多种因素所致的严重肝功能损伤,以黄疸、凝血功能紊乱、肝肾综合征、肝性脑病、腹水等为主要表现的一组临床综合征。其中,研究表明肝衰竭患者病情的进展与免疫功能失调及过度的全身炎症反应密切相关,在此过程中会释放出多种白细胞介素,通过与不同类型细胞上表达的特定受体结合,从而在宏观及微循环上发生改变。白介素的释放损害宿主的防御机制,使肝衰竭患者免疫功能低下,更容易受到继发感染,因而导致更高的器官功能障碍和病死率。白介素家族具有重叠但也不同的生物学活性,共同参与调节肝脏纤维化、免疫细胞刺激、损伤和修复之间的平衡,并且在多种炎症条件下都具有病理生理作用,与肝衰竭过程中的肝细胞坏死和疾病临床预后密切相关。本文旨在系统总结目前国内外白细胞介素与肝功能衰竭的关系及其相关机制的研究进展。

刘晶雪, 李树臣. 白细胞介素与肝功能衰竭的关系及其相关机制的研究[J]. 肝脏, 2023, 28(5): 611-613.

参考文献

[1] Fischer J,Silva TE,Soares E,et al.From stable disease to acute-on-chronic liver failure: Circulating cytokines are related to prognosis in different stages of cirrhosis.Cytokine,2017,91: 162-169.
[2] Clària J,Arroyo V,Moreau R.The acute-on-chronic liver failure syndrome,or when the innate immune system goes astray. J Immunol,2016,197(10): 3755-3761.
[3] 李雷.细胞因子与肝衰竭的关系及人工肝治疗对其变化的影响.南昌大学学报,2021.
[4] Dong V,Nanchal R,Karvellas CJ.Pathophysiology of acute liver failure.Nutr Clin Pract,2020,35(1): 24-29.
[5] Sarin SK,Choudhury A,Sharma MK,et al.Acute-on-chronic liver failure:consensus recommendations of the Asian Pacific Association for the Study of the Liver (APASL):an update.Hepatol Int,2019,13(4): 353-390.
[6] Casulleras M,Zhang IW,López-Vicario C,et al. Systemic inflammation and immunopathology in acute-on-chronic liver failure.Cells,2020,9(12) :2632.
[7] Lin JX,Leonard WJ.Fine-tuning cytokine signals.Annu Rev Immunol,2019,37(12): 295-324.
[8] Triantafyllou E,Woollard KJ,McPhail M,et al.The role of monocytes and macrophages in acute and acute-on-chronic liver failure.Front Immunol,2018,9: 2948.
[9] He Y,Hwang S,Ahmed YA,et al.Immunopathobiology and therapeutic targets related to cytokines in liver diseases.Cell Mol Immunol,2021,18(1): 18-37.
[10] Schmidt-Arras D,Rose-John S.IL-6 pathway in the liver:From physiopathology to therapy.J Hepatol,2016,64(6): 1403-1415.
[11] Li L,Chen L,Lin F,et al.Study of the expression of inflammatory factors IL-4,IL-6,IL-10,and IL-17 in liver failure complicated by coagulation dysfunction and sepsis.J Inflamm Res,2021,14: 1447-1453.
[12] Hunter CA,Jones SA.IL-6 as a keystone cytokine in health and disease.Nat Immunol,2015,16(5): 448-457.
[13] Kaur S,Bansal Y,Kumar R,et al.A panoramic review of IL-6:Structure,pathophysiological roles and inhibitors.Bioorg Med Chem,2020,28(5): 115327.
[14] 陈智,朱海红,杨英.细胞因子风暴与肝衰竭.临床肝胆病杂志,2014,30(10): 981-983.
[15] Widjaja AA,Chothani SP,Cook SA.Different roles of interleukin 6 and interleukin 11 in the liver: implications for therapy.Hum Vaccin Immunother,2020,16(10): 2357-2362.
[16] Tsutsui H,Cai X,Hayashi S.Interleukin-1 family cytokines in liver diseases.Mediators Inflamm,2015,2015: 630265.
[17] Chan AH,Schroder K.Inflammasome signaling and regulation of interleukin-1 family cytokines.J Exp Med,2020,217(1).
[18] Barbier L,Ferhat M,Salamé E,et al.Interleukin-1 family cytokines:Keystones in liver inflammatory diseases.Front Immunol,2019,10: 2014.
[19] Gehrke N,Hövelmeyer N,Waisman A,et al.Hepatocyte-specific deletion of IL1-RI attenuates liver injury by blocking IL-1 driven autoinflammation.J Hepatol,2018,68(5): 986-995.
[20] Roth GA,Zimmermann M,Lubsczyk BA,et al.Up-regulation of interleukin 33 and soluble ST2 serum levels in liver failure.J Surg Res,2010,163(2): e79-83.
[21] Cayrol C.IL-33,an alarmin of the IL-1 family involved in allergic and non allergic inflammation: Focus on the mechanisms of regulation of its activity.Cells,2021,11(1).
[22] Antunes MM,Araújo AM,Diniz AB,et al.IL-33 signalling in liver immune cells enhances drug-induced liver injury and inflammation.Inflamm Res,2018,67(1): 77-88.
[23] Arshad MI,Patrat-Delon S,Piquet-Pellorce C,et al.Pathogenic mouse hepatitis virus or poly(I:C) induce IL-33 in hepatocytes in murine models of hepatitis.PLoS One,2013,8(9): e74278.
[24] Mantovani A,Dinarello CA,Molgora M,et al.Interleukin-1 and related cytokines in the regulation of inflammation and immunity.Immunity,2019,50(4): 778-795.
[25] Luan J,Ju D.Inflammasome:A double-edged sword in liver diseases.Front Immunol,2018,9: 2201.
[26] Liu Y,Meng X,Wang C,et al.Interleukin-18 plays a positive feedback activity to natural killer-like b cells in hepatitis B virus-associated acute-on-chronic liver failure.Viral Immunol,2022,35(1): 50-59.
[27] Wu Y,Min J,Ge C,et al.Interleukin 22 in liver injury,inflammation and cancer.Int J Biol Sci,2020,16(13): 2405-2413.
[28] Martin-Mateos R,Alvarez-Mon M,Albillos A.Dysfunctional immune response in acute-on-chronic liver failure:It takes two to tango.Front Immunol,2019,10: 973.
[29] Caparrós E,Francés R.The interleukin-20 cytokine family in liver disease.Front Immunol,2018,9: 1155.
[30] Zai W,Chen W,Liu H,Ju D.Therapeutic opportunities of IL-22 in non-alcoholic fatty liver disease: From molecular mechanisms to clinical applications.Biomedicines,2021,9(12).
[31] Kleinschmidt D,Giannou AD,McGee HM,et al.A Protective function of IL-22bp in ischemia reperfusion and acetaminophen-induced liver injury.J Immunol,2017,199(12): 4078-4090.
[32] Ouyang W,O'Garra A.IL-10 Family cytokines IL-10 and IL-22:from basic science to clinical translation.Immunity,2019,50(4): 871-891.